Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis:First case report

作     者：Katsuyoshi Tamaki Akihiko Okubo 

作者机构：Department of HepatologyTourai-kai Okubo HospitalTokushima 770-0923Japan Department of RespirologyTourai-kai Okubo HospitalTokushima 770-0923Japan 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第3期

页      面：1009-1013页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Simeprevir Chronic hepatitis C Interstitial pneumo 

摘      要：The effectiveness of hepatitis C treatment has improved with the development of interferon(IFN),and it has drastically improved with the development of peg-interferon-α(PEG-IFN) in combination with ribavirin(RBV) and,more recently,with the addition of a protease ***,which is a secondgeneration protease inhibitor,has shown clinically favorable safety and tolerability *** received its first global approval in Japan in September 2013 for the treatment of genotype 1 chronic hepatitis C in combination with PEG-IFN and *** serious adverse event associated with IFN therapy is interstitialpneumonitis,which can be *** experienced a patient with interstitial pneumonitis that was induced by simeprevir with PEG-IFN and RBV therapy for chronic hepatitis C in the early stages of therapy(8 wk after initiating therapy).This is the first case report of interstitial pneumonitis with simeprevir with PEG-IFN and RBV in the *** addition,it is very interesting that the onset of interstitial pneumonitis was earlier than that in conventional PEG-IFN and RBV *** finding suggests that simeprevir augments the adverse *** present this case report in light of relevant literature on interstitial pneumonitis with conventional PEG-IFN and RBV therapy.